Evidence map›Paper›PMID 42910326›Full record

ArticleRSC advances2026

An activatable fluorescent probe for fibroblast activation protein α and its bioimaging applications.

Lei Feng, Hengjing Chen, Zhenhao Tian, Wenpeng Li, Yifei Dang, Guobiao Liang, Chengjuan Xing, Xiaohong Shu, Jing Ning, Fangyu Yang and 1 more

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lei FengSecond Affiliated Hospital, Dalian Medical University Dalian 116023 China maxc1978@163.com.ORCID https://orcid.org/0000-0003-2377-0190
Hengjing ChenSecond Affiliated Hospital, Dalian Medical University Dalian 116023 China maxc1978@163.com.
Zhenhao TianSchool of Life Science and Technology, Northwestern Polytechnical University Xi'an 710072 China.
Wenpeng LiCollege of Pharmacy, Dalian Medical University Dalian 116044 China ningjing0626@163.com.
Yifei DangCollege of Pharmacy, Dalian Medical University Dalian 116044 China ningjing0626@163.com.
Guobiao LiangDepartment of Neurosurgery, General Hospital of Northern Theater Command Shenyang China liangguobiao6708@vip.163.com.
Chengjuan XingSecond Affiliated Hospital, Dalian Medical University Dalian 116023 China maxc1978@163.com.
Xiaohong ShuCollege of Pharmacy, Dalian Medical University Dalian 116044 China ningjing0626@163.com.
Jing NingCollege of Pharmacy, Dalian Medical University Dalian 116044 China ningjing0626@163.com.ORCID https://orcid.org/0000-0002-8035-6802
Fangyu YangDepartment of Neurosurgery, General Hospital of Northern Theater Command Shenyang China liangguobiao6708@vip.163.com.
Xiaochi MaSecond Affiliated Hospital, Dalian Medical University Dalian 116023 China maxc1978@163.com.ORCID https://orcid.org/0000-0003-4397-537X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein α (FAP) is a member of the plasma membrane-bound serine protease family, which exhibits exopeptidase and endopeptidase activity in organisms. Recently, considerable studies have focused on the key role of FAP in various pathological processes, indicating that it may be a therapeutic target for treating human disorders and diseases. In the present study, a fluorescent probe for FAP was constructed by the introduction of a substrate recognition dipeptide that was rationally modified by

Identifiers

PMID42910326
PMCPMC13686149

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.